Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Non-Current Assets (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Non-Current Assets for 3 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 12.77% to $18.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $79.2 million, a 46.28% decrease, with the full-year FY2025 number at $18.3 million, down 12.77% from a year prior.
  • Non-Current Assets was $18.3 million for Q4 2025 at Artiva Biotherapeutics, down from $19.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $75.0 million in Q3 2024 to a low of $18.3 million in Q4 2025.
  • A 3-year average of $28.3 million and a median of $21.1 million in 2024 define the central range for Non-Current Assets.
  • Biggest YoY gain for Non-Current Assets was 12.77% in 2025; the steepest drop was 74.23% in 2025.
  • Artiva Biotherapeutics' Non-Current Assets stood at $25.3 million in 2023, then decreased by 17.17% to $21.0 million in 2024, then decreased by 12.77% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Non-Current Assets are $18.3 million (Q4 2025), $19.3 million (Q3 2025), and $20.3 million (Q2 2025).